trabectedin
Trabectedin is a drug used to treat Sarcoma, Soft Tissue Sarcoma, Leiomyosarcoma, and other conditions. Trabectedin is being actively studied in 13 studies and prior, has been studied in 38.
Top Sponsors | Top Sites | Top Investigators |
---|---|---|
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Institut Bergonie | Eric Kampmann |
Italian Sarcoma Group | Centre Leon Berard | Marilyn Huang |
European Organisation for Research and Treatment of Cancer - EORTC | Istituto Clinico Humanitas | Michele Reni |
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
G
Completed
- Uterine or Soft Tissue Leiomyosarcoma
- Doxorubicin
- Trabectedin
- Villejuif, Val De Marne, FranceGustave Roussy
2021-12-10
Dec 10, 2021U
Recruiting
- Sarcoma
- Sarcoma Metastatic
- Olaparib
- Trabectedin
- Ann Arbor, MichiganUniversity of Michigan Rogel Cancer Center
2021-12-15
Dec 15, 2021I
Recruiting
- Soft Tissue Sarcoma Adult
- +6 more
- Trabectedin
- Bordeaux, FranceInstitut Bergonie
2022-02-01
Feb 1, 2022F
Completed
- Carcinosarcoma, Ovarian
- Carcinosarcomas Uterine
- Trabectedin
- Rome, ItalyFondazione Policlinico Universitario Agostino Gemelli IRCCS
2021-08-24
Aug 24, 2021I
Active, not recruiting
- Mesenchymal Chondrosarcoma
- Trabectedin
- Prato, Firenze, Italy
- +5 more
2021-10-29
Oct 29, 2021G
Recruiting
- Soft Tissue Sarcoma
- +2 more
- Trabectedin
- Barcelona, Cataluña, Spain
- +6 more
2021-11-23
Nov 23, 2021F
Completed
- Ovarian Neoplasms
- Trabectedin
- +5 more
- Rome, ItalyDomenica Lorusso
2021-08-24
Aug 24, 2021I
Recruiting
- Solitary Fibrous Tumors
- Trabectedin
- +2 more
- Prato, Firenze, Italy
- +5 more
2021-10-29
Oct 29, 2021I
Completed
- Soft Tissue Sarcoma
- Bone Tumor
- trabectedin
- olaparib
- Candiolo, Torino, Italy
- +2 more
2021-04-13
Apr 13, 2021M
Not yet recruiting
- Liposarcoma, Myxoid
- +2 more
- Trabectedin
- Pioglitazone Oral Product
- (no location specified)
2021-03-10
Mar 10, 2021F
Terminated
- Metastatic Leiomyosarcoma
- +3 more
- Avelumab
- Trabectedin
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2020-11-16
Nov 16, 2020S
SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma
Recruiting
- Advanced Soft Tissue Sarcoma
- Metastatic Soft Tissue Sarcoma
- Trabectedin
- +2 more
- Santa Monica, CaliforniaSarcoma Oncology Research Center
2021-05-05
May 5, 2021I
Active, not recruiting
- Leiomyosarcoma of Ovary
- Soft Tissue Sarcoma
- Trabectedin
- +2 more
- Bologna, BO, Italy
- +12 more
2021-10-29
Oct 29, 2021S
Recruiting
- Leiomyosarcoma
- Trabectedin
- Santa Monica, CaliforniaSant P Chawla
2021-09-09
Sep 9, 2021I
Completed
- Liposarcoma
- Leiomyosarcoma
- Trabectedin
- Bari, BA, Italy
- +20 more
2021-10-29
Oct 29, 2021C
Completed
- Sarcoma
- Trabectedin
- (no location specified)
2020-05-15
May 15, 2020U
Active, not recruiting
- Metastatic Adult Soft Tissue Sarcoma
- Trabectedin
- Nivolumab
- Bad Saarow, Germany
- +8 more
2021-02-19
Feb 19, 2021E
Terminated
- Sarcoma, Soft Tissue
- Trabectedin
- Bordeaux, France
- +13 more
2020-09-01
Sep 1, 2020M
Withdrawn
- Refractory Chronic Lymphocytic Leukemia
- Refractory Small Lymphocytic Lymphoma
- Trabectedin
- Venetoclax
- Houston, TexasM D Anderson Cancer Center
2020-03-11
Mar 11, 2020N
Recruiting
- Cancers With DNA Repair-Deficiency
- Olaparib
- +2 more
- Dresden, Germany
- +8 more
2022-01-12
Jan 12, 2022G
Unknown status
- Liposarcoma, Myxoid
- +4 more
- Trabectedin
- Radiotherapy
- Bordeaux, France
- +15 more
2020-04-27
Apr 27, 2020M
Completed
- Malignant Pleural Mesothelioma
- Trabectedin
- Alessandria, AL, Italy
- +7 more
2020-01-22
Jan 22, 2020F
Withdrawn
- Myxoid Liposarcoma
- +5 more
- Biopsy
- +2 more
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2019-09-06
Sep 6, 2019L
Recruiting
- Sarcoma
- Trabectedin
- DNA double-strand breaks
- Munich, Bavaria, Germany
- +4 more
2019-07-11
Jul 11, 2019P
Completed
- Relapsed Ovarian Cancer
- trabectedin
- Aalst, Flandes, Belgium
- +64 more
2021-09-30
Sep 30, 2021